|
|
 |
| |
|
Home > Drug News > CME Outfitters Announces Live psychCME TV Activity
CME Outfitters Announces Live psychCME TV Activity
Rockville, MD (PRWEB) July 12, 2005 -- CME Outfitters, LLC, nationally accredited provider of multidisciplinary medical education programming and related healthcare communications services, is pleased to announce an upcoming live and interactive CE activity titled "Reducing Relapse: Case-Based Strategies for Achieving Successful Long-Term Outcomes in Patients with Schizophrenia." Offered as a live satellite broadcast, webcast, and telephone audioconference premiering Wednesday, August 10, 2005, from 12:00 p.m.–1:00 p.m. ET, the activity will focus on providing case- and evidence-based educational information regarding the neurochemical basis of relapse in schizophrenia and offering novel strategies for reducing and preventing relapse. The recorded satellite broadcast will re-air from 3:00 p.m.–4:00 p.m. ET. This CE activity will be available as an archived webcast, podcast, and telephone audioconference shortly after the live broadcast, and available as a videotape or multimedia CD-ROM in September.
Statement of Need:
Schizophrenia is a severe, debilitating mental illness characterized by a progressive decline in a patient’s functioning and relationship with the outside world. Although some patients recover, the risk for relapse after a schizophrenic episode remains elevated throughout the patient’s lifetime. Moreover, the risk for chronicity increases with every relapse. Therefore, one of the main goals of treatment is more effective reduction of relapse and recurrence. Studies show that atypical antipsychotics have advantages in preventing relapse of schizophrenia compared with the conventional antipsychotics in first episode patients, and even among previously stable, nonremitted patients. Many of these patients achieve symptom remission with significant improvements in multiple symptom domains and patient-rated health status after switching to atypical antipsychotics with assured compliance. Several neurotransmitter systems have been implicated in the neurobiology of schizophrenia, including dopamine, glutamate, serotonin, and norepinephrine. This case-based psychCME TV activity will explore the neurobiology of relapse in schizophrenia, define parameters that contribute to relapse, and offer novel interventions to reduce and prevent relapse and improve long-term functional outcomes.
Back to Drug News
|
|
|
|
|
|
|
|